250 related articles for article (PubMed ID: 38359439)
1. Advances in targeted therapy of cholangiocarcinoma.
Li Y; Yu J; Zhang Y; Peng C; Song Y; Liu S
Ann Med; 2024 Dec; 56(1):2310196. PubMed ID: 38359439
[TBL] [Abstract][Full Text] [Related]
2. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
[TBL] [Abstract][Full Text] [Related]
3. Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
Zhang X; Tang H; Fan J; Wang R; Han Y; Su S; Gan Y; Peng F; Rao M; Zhang J; Li B; Yang X
Front Immunol; 2022; 13():1051130. PubMed ID: 36618353
[TBL] [Abstract][Full Text] [Related]
4. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
5. Cholangiocellular Carcinoma.
Vogel A; Saborowski A
Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
7. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
8. Advances in research and application of photodynamic therapy in cholangiocarcinoma (Review).
Li Y; Li Y; Song Y; Liu S
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38334150
[TBL] [Abstract][Full Text] [Related]
9. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
10. Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs.
Spolverato G; Glavas D; Hewitt DB; Brown ZJ; Capelli G; Bergamo F; Rizzato MD; Pawlik TM
Expert Opin Pharmacother; 2022 Mar; 23(4):473-481. PubMed ID: 34964678
[TBL] [Abstract][Full Text] [Related]
11. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
12. Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma.
Trojan J; Hoffmeister A; Neu B; Kasper S; Dechêne A; Jürgensen C; Schirra J; Jakobs R; Palmer D; Selbo PK; Olivecrona H; Finnesand L; Høgset A; Walday P; Sturgess R
Oncologist; 2022 Jun; 27(6):430-e433. PubMed ID: 35675633
[TBL] [Abstract][Full Text] [Related]
13. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
Suksawat M; Phetcharaburanin J; Klanrit P; Namwat N; Khuntikeo N; Titapun A; Jarearnrat A; Vilayhong V; Sa-Ngiamwibool P; Techasen A; Wangwiwatsin A; Mahalapbutr P; Li JV; Loilome W
Front Public Health; 2022; 10():766023. PubMed ID: 35223723
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
16. Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
Ottaiano A; Santorsola M; Diana A; Belli A; Lentini Graziano ML; Orefice J; Patrone R; Di Mauro A; Scognamiglio G; Tatangelo F; De Bellis M; Piccirillo M; Fiore F; Stilo S; Tarotto L; Correra M; Di Lorenzo S; Capuozzo M; Avallone A; Silvestro L; Bianco A; Granata V; Federico P; Montesarchio V; Daniele B; Izzo F; Nasti G
Cancer Med; 2024 Feb; 13(4):e6892. PubMed ID: 38457226
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Virchow I; Treckmann JW; Prasnikar N; Linden G; Markus P; Schumacher B; Albers D; Herold T; Ting S; Schmidt H; Radunz S; Wiesweg M; Siveke J; Schuler M; Kasper S
Oncol Res Treat; 2023; 46(3):89-99. PubMed ID: 36623497
[TBL] [Abstract][Full Text] [Related]
18. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
20. Cholangiocarcinoma Therapeutics: An Update.
Nguyen MLT; Toan NL; Bozko M; Bui KC; Bozko P
Curr Cancer Drug Targets; 2021; 21(6):457-475. PubMed ID: 33563168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
